XELJANZ: payments to doctors
Payments that named XELJANZ as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $14.5M
- Providers
- 19,075
- Transactions
- 244,492
- Average per transaction
- $59
The per-transaction average — $59 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 19,075 providers the average total is $758, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $14,313,509 | 99.0% |
| Whitehall International Inc | $115,696 | 0.8% |
| Pfizer Pharmaceuticals LLC | $13,119 | 0.1% |
| PBG Puerto RICO LLC | $12,183 | 0.1% |
| Pfizer Chile S.A. | $6,300 | 0.0% |
| Pfizer Pharmaceuticals Korea Limited | $36 | 0.0% |